BDBM520509 US11130769, Ex. No. 208::[(3R,6R,7S,8E,22S)-6′-Chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazine-8-carboxylate

SMILES CN1C\C=C\[C@H](OC(=O)N2CCN3CCOC[C@H]3C2)[C@@H]2CC[C@H]2CN2C[C@@]3(CCCc4cc(Cl)ccc34)COc3ccc(cc23)S(=O)(=O)NC(=O)C1(C)C

InChI Key InChIKey=OAGCPMPYEINYBV-KQULDXDGSA-N

Data  1 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 520509   

TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Prelude Therapeutics

US Patent
LigandPNGBDBM520509(US11130769, Ex. No. 208 | [(3R,6R,7S,8E,22S)-6R...)
Affinity DataKi: <100nMAssay Description:The assay was carried out in black half-area 96-well NBS plate (Corning), containing 15 nM of MCL-1 (BPS Bioscience), 5 nM of FITC-Bim and 3-fold ser...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent